Deprecated: Function WP_Dependencies->add_data() was called with an argument that is deprecated since version 6.9.0! IE conditional comments are ignored by all supported browsers. in /home/foxlogica/public_html/psx/wp-includes/functions.php on line 6131
⏸️ AGIC: HOLD Signal (5/10) - AGIC - Right Issue (R-5) Subscription Status - FoxLogica

⚡ Flash Summary

Askari General Insurance Co. Ltd. announced the subscription status of its right issue (R-5) on December 5th, 2025. The total issue size was PKR 920,344,256/-, with subscriptions received amounting to PKR 888,878,144/-. This represents a subscription rate of 96.58%, leaving an unsubscribed portion of PKR 31,466,112/-, or 3.42%. The Board of Directors will allot the unsubscribed shares in accordance with the Companies Act, 2017.

Signal: HOLD ⏸️
Strength: 5/10
Sentiment: NEUTRAL
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • ✅ Right issue (R-5) subscription status announced by Askari General Insurance.
  • 📅 Announcement date: December 5th, 2025.
  • 💰 Total issue size: PKR 920,344,256/-.
  • 📈 Subscription received: PKR 888,878,144/-.
  • ✔️ Subscription rate: 96.58%.
  • ⚠️ Unsubscribed portion: PKR 31,466,112/-.
  • 📉 Unsubscribed portion percentage: 3.42%.
  • 📜 Allotment of unsubscribed shares as per Companies Act, 2017.
  • 🏦 Bankers to the Issue and Central Depository Company of Pakistan Limited reported the subscription amount.
  • 🗓️ Last date of subscription: December 1st, 2025.
  • 📢 TREC Holders of the Exchange will be informed accordingly.
  • 💼 Board of Directors to decide on the allotment of unsubscribed portion.
  • ✔ Auditors Certificate confirming receipt of Right Issue will be communicated to the Exchange.
  • 🇵🇰 The announcement is in reference to the Pakistan Stock Exchange’s procedure.

🎯 Investment Thesis

HOLD. The nearly full subscription of the right issue indicates investor confidence, but the small unsubscribed portion introduces some uncertainty. A hold recommendation is appropriate until the company successfully deploys the capital and demonstrates improved financial performance. The price target will depend on the future earnings and growth prospects after the capital infusion. We will revisit in Q2 2026 after reviewing their financials.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Leave a Comment